Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells (Beike Biotechnology)
- Development stage
- Unknown
- Lead developer
- Beike Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Shenzhen Beike Biotechnology's human umbilical cord mesenchymal stem cell (hUC-MSC) therapy is an allogeneic cell-based product derived from Wharton's jelly. Developed for the treatment of moderate to severe, active, and refractory systemic lupus erythematosus (SLE), the therapy utilizes the immunomodulatory properties of mesenchymal stem cells to restore immune homeostasis. The mechanism involves the rebalancing of immune cell populations, particularly the CD4+/CD8+ T cell ratio, and the suppression of inflammatory responses. Clinical studies, including Phase I/II trials, have evaluated the safety and efficacy of these cells when administered via intravenous injection, showing potential in reducing disease activity in patients who are non-responsive to conventional treatments.
- Other names
- umbilical cord-derived mesenchymal stem cellsallogeneic mesenchymal stem cellshUC-MSC
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells (Beike Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Beike Biotechnology).